GlycoPath

GlycoPath Inc. was founded in 2019 as a bioanalytical testing technology development company. GlycoPath acquired the GlycoTyper platform technology from the Medical University of South Carolina, which is capable of measuring glycans of multiple captured glycoprotein targets in a high-throughput single assay. The platform can perform hundreds to thousands of glycan measurements per day, making it suitable for various bioanalyses in drug development and clinical diagnostics. Currently, the platform's immunoaffinity slides and glycan analysis reagents have been configured for glycan analysis in the fields of hepatology, oncology, infectious diseases, and pharmaceuticals.